Derived neutrophil-to-lymphocyte ratio predicts pathological complete response to neoadjuvant chemotherapy in breast cancer

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Ocaña, Alberto
• dc.contributor.author Albanell Mestres, Joan
• dc.contributor.author Gianni, Luca
• dc.date.accessioned 2023-07-10T06:53:17Z
• dc.date.available 2023-07-10T06:53:17Z
• dc.date.issued 2022
• dc.description.abstract Background: Derived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with clinical outcome in breast cancer (BC). We analyzed the association of dNLR with pathological complete response (pCR) in triple-negative BC (TNBC) patients receiving neoadjuvant chemotherapy (CT). Methods: This is a retrospective analysis of two randomized studies involving early stage/locally advanced TNBC patients receiving anthracycline/taxane-based CT+/-carboplatin (GEICAM/2006-03) or nab-paclitaxel/paclitaxel followed by anthracycline regimen (ETNA). dNLR was calculated as the ratio of neutrophils to the difference between total leukocytes and neutrophils in peripheral blood before CT (baseline) and at the end of treatment (EOT). Logistic regression analyses were used to explore dNLR association with pCR. Results: In total, 308 TNBC patients were analyzed, 216 from ETNA and 92 from GEICAM/2006-03. Baseline median dNLR was 1.61 (interquartile range (IQR): 1.25-2.04) and at EOT 1.53 (IQR: 0.96-2.22). Baseline dNLR showed positive correlation with increased tumor size (p-value = 1e-04). High baseline dNLR, as continuous variable or using median cutoff, was associated with lower likelihood of pCR in univariate analysis. High EOT dNLR as continuous variable or using quartiles was also associated with lower pCR rate in uni- and multivariate analyses. Conclusions: High baseline and EOT dNLR correlates with lower benefit from neoadjuvant CT in TNBC.
• dc.format.mimetype application/pdf
• dc.identifier.citation Ocaña A, Chacón JI, Calvo L, Antón A, Mansutti M, Albanell J, et al. Derived neutrophil-to-lymphocyte ratio predicts pathological complete response to neoadjuvant chemotherapy in breast cancer. Front Oncol. 2022 Feb 11;11:827625. DOI: 10.3389/fonc.2021.827625
• dc.identifier.doi http://dx.doi.org/10.3389/fonc.2021.827625
• dc.identifier.issn 2234-943X
• dc.identifier.uri http://hdl.handle.net/10230/57508
• dc.language.iso eng
• dc.publisher Frontiers
• dc.relation.ispartof Front Oncol. 2022 Feb 11;11:827625
• dc.rights © 2022 Ocaña, Chacón, Calvo, Antón, Mansutti, Albanell, Martínez, Lahuerta, Bisagni, Bermejo, Semiglazov, Thill, Chan, Morales, Herranz, Tusquets, Chiesa, Caballero, Valagussa, Bianchini, Alba and Gianni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword DNLR
• dc.subject.keyword PCR
• dc.subject.keyword Breast cancer
• dc.subject.keyword Immunology
• dc.subject.keyword Neoadjuvant chemotherapy
• dc.title Derived neutrophil-to-lymphocyte ratio predicts pathological complete response to neoadjuvant chemotherapy in breast cancer
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion